↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Gagnon C, Gomez-Mancilla B, Markstein R, Bédard PJ, Di Paolo T (July 1995). „Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors”. Progress in Neuro-psychopharmacology & Biological Psychiatry19 (4): 667–76. PMID8588064.
↑Beninger RJ, Rolfe NG (December 1995). „Dopamine D1-like receptor agonists impair responding for conditioned reward in rats”. Behavioural Pharmacology6 (8): 785–793. PMID11224381.
↑Luquin MR, Guillén J, Legarda I, Cruz Rodriguez M, Del Rio L, Dominguez J, Martínez-Lage JM (1996). „Pulsatile administration of D1 but not D2 dopamine agonists induces behavioral tolerance in MPTP-treated monkeys”. Advances in Neurology69: 239–44. PMID8615134.
↑D'Aquila PS, Panin F, Cossu M, Peana AT, Serra G (January 2003). „Dopamine D1 receptor agonists induce penile erections in rats”. European Journal of Pharmacology460 (1): 71–4. DOI:10.1016/S0014-2999(02)02881-9. PMID12535862.
↑Salamone JD, Carlson BB, Rios C, Lentini E, Correa M, Wisniecki A, Betz A (January 2005). „Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243”. Behavioural Brain Research156 (2): 173–9. DOI:10.1016/j.bbr.2004.05.019. PMID15582103.